Stock CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation
MT
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
AQ
Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target
MT
Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $525,873, According to a Recent SEC Filing
MT
Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target
MT
Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
MT
Celldex Therapeutics to Present at Jefferies Healthcare Conference
AQ
Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing
MT
Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing
MT
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
AQ
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024
CI
Certain Common Stock of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Certain Stock Options of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
CI
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
MT
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
AQ
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
CI
Celldex: Q1 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. Stock
  5. News Celldex Therapeutics, Inc.